Catalyst ligands

1662-01-7, 4,7-Diphenyl-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The chloro-bridged dimeric iridium complex[Ir(ppz)2Cl]2 (123 mg, 0.12 mmol) and 4,7-diphenyl-1,10-phenanthroline (88 mg, 0.26 mmol) were dissolved in CH2Cl2 (15 ml) and MeOH (15 ml). The mixture was refluxed under nitrogen for 12 h and the yellow solution obtained was cooled to room temperature and solid ammonium tetrafluoroborate (52 mg, 0.5 mmol) was added to it. The reaction mixture was stirred at room temperature for 1 h and the solvent was evaporated under vacuum. The product obtained was dissolved in dichloromethane, filtered to remove the unwanted inorganic impurities, and then precipitated with hexane. The crude material obtained was purified by column chromatography (Merck Alox 90; CH2Cl2 changing toCH2Cl2/MeOH, 100:2) yielding the desired product as yellow solid (156 mg, 0.17 mmol,73%). The chemical structure of the cationic iridium complex is shown in Fig. 1. 1H NMR(500 MHz, CD2Cl2) delta (ppm): 8.50 (d, J = 5.2 Hz, 2H), 8.13 (d, J = 3.1 Hz, 2H), 7.66 (d, J = 5.1 Hz, 2H), 7.61-7.54 (m, 4H), 7.33 (d, J = 7.1 Hz, 2H), 7.26 (d, J = 2.93 Hz, 2H),7.11-7.07 (m, 4H), 6.98-6.92 (m, 4H), 6.54 (t, 5.1 Hz, 1H), 6.48-6.46 (m, 1H). 13C NMR(126 MHz, CD2Cl2) delta (ppm): 151.6, 150.8, 148.3, 143.5, 139.0, 135.8, 130.3, 129.9, 129.7,129.4, 127.2, 126.9, 126.5, 123.6, 121.7, 111.7, 108.7. Anal. Found (%): C 56.25, H 3.45,N 9.34. Anal. Calcd for C42H30N6BF4Ir: C 56.19, H 3.37, N 9.36., 1662-01-7

1662-01-7 4,7-Diphenyl-1,10-phenanthroline 72812, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Sunesh, Chozhidakath Damodharan; Chandran, Midhun; Ok, Sunseong; Choe, Youngson; Molecular Crystals and Liquid Crystals; vol. 584; 1; (2013); p. 131 – 138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.

To a solution of (25,5 ?)-6- (benzyloxy)-7-oxo-N-[2-(2H-l,2,3-triazol-2-yl)ethoxy]-l,6-diazabicyclo[3.2.1]octane-2- carboxamide (4 g, 10.3 mmol, upper spot as per thin layer chromatography in Step 3) in dimethylformamide (20 ml) and dichloromethane (20 ml) was added palladium over carbon (10%, 1.0 g) under nitrogen atmosphere. The reaction mixture was flushed with hydrogen gas and stirred for 3 hour under hydrogen pressure (55 psi). The progress of reaction was monitored by thin layer chromatography using mixture of chloroform and methanol (9: 1) as solvent system. After complete conversion, the reaction mixture was filtered through celite bed and washed with a mixture of dichloromethane and dimethylformamide (20 ml, 1: 1). The collected filtrate was evaporated under reduced pressure to dryness. The intermediate thus obtained was dissolved into dimethylformamide (20 ml) and dimethylformamide sulfur trioxide complex (2.4 g, 15.6 mmol) was added under stirring at 0 C. The reaction mixture was allowed to attain ambient temperature and stirred further for 1 hour. The completion of reaction was monitored by performing thin layer chromatography using mixture of chloroform and methanol as solvent system. After complete conversion, the reaction mixture was cooled to 0C and then a solution of tetra butyl ammonium acetate (5 g, 16.5 mmol) in water (17 ml) was slowly added under stirring. After 1 hour, the reaction mixture was concentrated to dryness in vacuum and co-evaporated with xylene (2×30 ml) to dimethylformamide free mass. To this concentrated mass, water (40 ml) was added and then extraction with dichloromethane was carried (2×40 ml). The collective organic layer was dried on anhydrous sodium sulfate and concentrated to dryness to provide 8.5 g of crude compound. It was purified using column chromatography (silcagel 60- 120) by using mixture of dichloromethane and methanol as an eluent. The pure compound was isolated at 5% concentration of methanol in dichloromethane; the collective fractions were collected and evaporated to obtain 3.5 g of tetrabutyl ammonium salt of (25,5 ?)-7-oxo-6-(sulfooxy)-N-[2-(2H- l,2,3-triazol-2-yl)ethoxy]- l,6-diazabicyclo[3.2.1]octane- 2-carboxamide in 55% yield. Analysis: Mass: 375.2 (M- l, for free acid) for Molecular weight: 617 and Molecular formula: C27H5iN707S., 10534-59-5

The synthetic route of 10534-59-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; WOCKHARDT LIMITED; TADIPARTHI, Ravikumar; PATIL, Vijaykumar Jagdishwar; DEKHANE, Deepak; SHAIKH, Mohammad Usman; BIRAJDAR, Satish; DOND, Bharat; PATEL, Mahesh Vithalbhai; (100 pag.)WO2017/81615; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

448-61-3, 2,4,6-Triphenylpyrylium tetrafluoroborate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a suspension of the corresponding amine (2.0 mmol) and 2,4,6-triphenylpyrylium tetrafluoroborate (2.0 mmol) in EtOH (20 mL) in a round bottle flask was added Et3N (2.0 mmol). The mixture turned deep-brown while the educts dissolved and was stirred for 30 min at rt followed by the addition of AcOH (4.0 mmol) and heating under reflux conditions for additional 2 h. The product precipitated during the reaction. The product was dissolved directly in the flask with little acetone at the reflux temperature after the reaction was finished (no further precipitate occurred). After cooling down to rt the product crystallized as a yellow solid, which was filtered off, washed with cold EtOH and pentane and dried in vacuo., 448-61-3

The synthetic route of 448-61-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Menzel, Roberto; Kupfer, Stephan; Mede, Ralf; Goerls, Helmar; Gonzalez, Leticia; Beckert, Rainer; Tetrahedron; vol. 69; 5; (2013); p. 1489 – 1498;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

103946-54-9, 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

103946-54-9, 4,4′-Dimethyl-2,2′-bipyridine (1.5 g, 8 mmol) and selenium dioxide (887.68 mg, 8 mmol) were refluxed in 100 ml of 1,4-dioxane for 24 hours, after cooling to room temperature, the black solid was filtered off and solvent was removed by evaporation to give a white solid. This solid was dissolved by stirring with 100 ml of ethyl acetate, the insoluble material was filtered off, and the filtrate was washed three times with 20 ml of a 1.0 M sodium carbonate solution. The organic phase was extracted three times with 50 ml of 0.3 M sodium metabisulfite solution, the aqueous phase was combined, the pH was adjusted to 10 with sodium carbonate solution, and extracted four times with 20 ml of chloroform, the organic phase was combined, which was dried over anhydrous sodium sulfate and solvent was removed by evaporation to give a crude product. The crude product was purified by column chromatography eluting with petroleum ether / ethyl acetate (1: 4) to give aldehyde-substituted bipyridine 398 mg was obtained in a yield of 25%. The aldehyde-substituted bipyridine was dissolved in 20 ml of ethanol, stirred with 4 ml of a silver nitrate aqueous solution, then 10 ml of a 1.0 M aqueous sodium hydroxide solution was slowly added and reacted at room temperature for 15 hours. The solvent was removed by evaporation and the solid was washed twice with 4 ml of 1.3 M sodium hydroxide and 4 ml of water, the combined filtrate was extracted three times with 10 ml of chloroform, aqueous phase pH was 3.5 with 4 M hydrochloric acid, the resulting white solid was filtered and dried in vacuo to give carboxy-substituted bipyridine 258 mg, yield 60%. The resulting carboxyl substituted bipyridine (1.3 mmol) was all dissolved in 20 ml DMF, then aminothiazole compound (300 mg, 1.3 mmol), 1-hydroxy-7-azobenzotriazole (1.3 mmol, 177 mg), 4-dimethylaminopyridine (1.3 mmol, 146 mg), 1-ethyl-carbonyldiimide hydrochloride (1.3 mmol, 87 mg) were added thereto, and stirred at room temperature for 6 hours. The obtained solid was filtered, washed four times with 25 ml of water and dried in vacuo to give the Aminothiazole functional group-substituted polypyridine ligand (L1) 457 mg, yield 82%. All the obtained L1 (1.06 mmol) and the compound cis-[Ru(bpy)2Cl2].2H2O (442 mg, 0.85 mmol) were refluxed under 20 ml of ethylene glycol and argon gas protection for 8 hours. After cooling to room temperature, 10 ml of a saturated aqueous solution of ammonium hexafluorophosphate was added,the obtained orange precipitate was filtered, washed once with 15 ml of water, washed three times with 30 ml of anhydrous diethyl ether and dried in vacuo to give crude product. The crude product is subjected to neutral alumina column chromatography, and the only orange component is eluted with acetonitrile to obtain the target polypyridyl ruthenium complex Ru1, amount 616 mg, yield 64%

103946-54-9 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid 11127621, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Yunnan University; Gao Feng; Yan Ru; Bi Xudan; (15 pag.)CN109232663; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.

To a stirred solution of 2,4 dimethoxy benzaldehyde (0.542 g, 3.3 mmol) in tetrahydrofuran (10 ml.), was added N, N-diisopropyl ethyl amine (1.0 g, 7.0 mmol) followed by the addition of (25,5 ?)-N-(2-hydrazino-2-oxoethyl)-7-oxo-6-(sulfooxy)- l,6-diazabicyclo [3.2.1 ]octane-2- carboxamide (1 g, 3.0mmol) at 25C. The reaction mixture was stirred for 16 hours and to the resulting mixture was added a solution of tetrabutylammonium acetate (0.3 g, 3.0 mmol) in tetrahydrofuran (10 ml.) and stirring continued further for 24 hours. The solvent was evaporated under reduced pressure and the residue was taken up in dichloro methane (20 ml) and washed with 10% aqueous potassium hydrogen sulfate solution (3 ml x 2) and finally organic layer was washed with water (5 ml). The organic layer was separated and dried over anhydrous sodium sulfate and evaporated under reduced pressure to yield a semi solid residue. This was purified by column chromatography over silica-gel (60- 120 mesh) by eluting with mixture of methanol in dichloro methane (5: 95). The combined fractions were evaporated under reduced pressure to obtain 1.1 g of tetrabutylammonium salt of (25,5 ?)-N-{2-[(2E,Z)-2-(2,4-dimethoxybenzylidenehydrazino]-2-oxoethyl}-7-oxo-6-(sulfooxy)- l,6- diazabicyclo[3.2.1]octane-2-carboxamide as a white solid in 51%

10534-59-5, 10534-59-5 Tetrabutylammonium acetate 82707, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; WOCKHARDT LIMITED; PATIL, Vijaykumar Jagdishwar; TADIPARTHI, Ravikumar; LOGANANTHAN, Velupillai; DEKHANE, Deepak; SHAIKH, Mohammad Usman; BIRAJDAR, Satish; PAWAR, Mangesh; PATEL, Piyush Ambalal; JOSHI, Prashant Ratnakar; PATEL, Mahesh Vithalbhai; (57 pag.)WO2017/2089; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.14162-95-9,4-Bromo-2,2′-bipyridine,as a common compound, the synthetic route is as follows.,14162-95-9

General procedure: In a tube were added 6-bromo-2,2-bipyridine (70.5mg, 0.3mmol, 1equiv.), phenothiazine (77.7mg, 1.3equiv.), RuPhos-Pd-G2 (23.4mg, 10mol%) and t-BuOK (50.5mg, 1.5equiv). The tube was sealed, purged three times with argon and 1mL of anhydrous dioxane was added. The reaction mixture was stirred at 110C for 18h. After cooling to room temperature, 10mL of H2O were added and the aqueous layer was extracted three times with ethyl acetate (3¡Á10 mL). The combined organic layers were dried with MgSO4 and the solvent was removed under reduced pressure. The residue was purified by silica gel flash chromatography (50/50: CH2Cl2/cyclohexane) affording 51.2 mg of L1 (0.145 mmol, 48%) as an amorphous pale yellow solid.

As the paragraph descriping shows that 14162-95-9 is playing an increasingly important role.

Reference£º
Article; Tabey, Alexis; Mendy, Jonathan; Hermange, Philippe; Fouquet, Eric; Tetrahedron Letters; vol. 58; 32; (2017); p. 3096 – 3100;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A solution of 2,6-bis(bromomethyl)quinolineS7 (63.7 mg, 200 mumol) was added to solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (101 mg, 200 mumol), bis(pyridin-2-ylmethyl)amine (40.3 mg, 200 mumol) and K2CO3 (55.9 mg, 200 mumol) in CH3CN (2.50 mL) under N2 and stirred at 80 C for 48 h under microwave irradiation. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washed with water and brine, dried with Na2SO4 and concentrated in vacuo to obtain the corresponding tri-N-Boc-protected amine intermediates. The intermediates were then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds with the mixture of regioisomers 23AB., 170161-27-0

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

338-69-2, H-D-Ala-OH is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: SOCl2 (21.8mL, 0.3mol) and (S)-alanine ((S)-19, 8.91g, 0.1mol) were added to CH3OH (100mL) and the mixture was stirred at RT for 2h. The solvent was removed in vacuo, the residue was dissolved in methanol (30mL) and the organic solvent was removed in vacuo again. This procedure was repeated twice. Colorless amorphous solid, mp 103C (Ref. 39 mp 98-99C), yield 14.3g (>99%)., 338-69-2

As the paragraph descriping shows that 338-69-2 is playing an increasingly important role.

Reference£º
Article; Fanter, Lena; Mueller, Christoph; Schepmann, Dirk; Bracher, Franz; Wuensch, Bernhard; Bioorganic and Medicinal Chemistry; vol. 25; 17; (2017); p. 4778 – 4799;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4199-88-6,5-Nitro-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

Complex 1 was prepared by a conventional synthetic method, in which a mixture ofdichloromethane and methanol (42 mL, 2:1) was added to a flask containing [Ir(Hppy)2Cl]2 (0.323 g,0.30 mmol) and NP (0.135 g, 0.60 mmol) [19]. The mixture was refluxed for 6 h under argon to givea red brown solution. After cooling, a bright red precipitate was obtained by dropwise additionof concentrated NH4PF6 aqueous solution with stirring at room temperature for 2 h. The crudeproduct was purified by column chromatography on alumina eluted with dichloromethane-acetone(1:3, v/v). The red band was collected, the solvent was evaporated under the reduced pressure, and abrown-yellow powder was obtained. Yield: 86%. Anal. Calc for C34H23F6N5O2PIr: C, 46.90; H, 2.66;N, 8.04%. Found: C, 46.81; H, 2.72; N, 8.12%. 1H NMR (500 MHz, DMSO-d6): 9.46 (s, 1H), 9.20 (d, 1H,J = 8.0 Hz), 9.12 (d, 1H, J = 7.5 Hz), 8.34 (dd, 2H, J = 5.5, J = 6.0 Hz), 8.26 (d, 2H, J = 8.0 Hz), 8.19-8.15(m, 2H), 7.95 (d, 2H, J = 8.0 Hz), 7.88 (t, 2H, J = 7.5 Hz), 7.52 (dd, 2H, J = 6.0, J = 6.0 Hz), 7.06 (t, 2H,J = 7.5 Hz), 7.01-6.94 (m, 5H), 6.26 (d, 2H, J = 7.5 Hz). 13C NMR (125 Hz, DMSO-d6): 166.70, 153.41,151.88, 149.56, 149.11, 147.87, 146.79, 144.96, 144.04, 140.80, 138.87, 135.24, 131.23, 130.33, 128.52, 128.34,127.45, 125.14, 123.97, 123.89, 122.60, 120.03. ESI-MS (CH3CN): m/z 725.9 ([M-PF6]+)., 4199-88-6

As the paragraph descriping shows that 4199-88-6 is playing an increasingly important role.

Reference£º
Article; Zhang, Li-Xia; Gu, Yi-Ying; Wang, Yang-Jie; Bai, Lan; Du, Fan; Zhang, Wen-Yao; He, Miao; Liu, Yun-Jun; Chen, Yan-Zhong; Molecules; vol. 24; 17; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of 2 or 3 (0.50 mmol), the corresponding acids RCOOH (0.60 mmol),DCC (0.60 mmol), DMAP (0.1 mmol) in dry dichloromethane (15 mL) was stirred atroom temperature. When the reaction was completed, and checked by TLC, the mixturewas filtered to remove urea from the reaction, and the filtrate was diluted bydichloromethane (45 mL). Subsequently, the diluted organic phase was washed bysaturated aqueous NaHCO3 (30 mL), and brine (30 mL), dried over anhydrousNa2SO4, concentrated in vacuo, and purified by CC to give the pure 9R/S-acyloxyderivatives of cinchonidine and cinchonine 5a-j,l-o and 6a,c,e-o [17-19]. The dataof target compounds are shown as follows.

485-71-2, The synthetic route of 485-71-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Che, Zhi-Ping; Chen, Gen-Qiang; Jiang, Jia; Lin, Xiao-Min; Liu, Sheng-Ming; Sun, Di; Tian, Yue-E; Yang, Jin-Ming; Zhang, Song; Journal of Asian Natural Products Research; (2020);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI